UNSPSC 51321607: Inositol niacinate

This classification denotes an anti-lipidemic agent with the molecular formula C42H30N6O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A99MK953KZ, chemically known as 1,2,3,54,6 cyclohexanehexol hexanicotinate but more generally known as inositol hexanicotinate, which bears US NIH Compound Identifier 3720. European Medicines Agency schedules Inositol nicotinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08192MIG.

UNSPSC 51321607 Inositol niacinate, a Commodity code, covers pharmaceutical active ingredients and finished medications supplied to state and local health agencies, emergency services, and multistate cooperative purchasing consortiums. State and local governments procuring under this code buy emergency life support medications, generic pharmaceuticals for state health programs, and specialized prescription fulfillment through direct-to-manufacturer channels. Issuing bodies include municipal fire and rescue services, state health and human services departments, and multistate cooperative purchasing alliances (such as MMCAP). The scope ranges from acute-care emergency medications in small quantities for prehospital use to large-volume generic pharmaceutical contracts serving multiple jurisdictions and institutional healthcare settings.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) on April 24, 2026 for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and a response deadline of April 8, 2026, featuring a 5 percent Small Local Business Enterprise (SLBE) bid discount. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) on April 3, 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, with awarded contracts effective July 1, 2026, requiring products through authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC.